商業化培養基|奧浦邁-細胞培養基和端到端CDMO解決方案

<ol id="3sh72"><object id="3sh72"></object></ol>

<tbody id="3sh72"><pre id="3sh72"></pre></tbody>

<em id="3sh72"><acronym id="3sh72"></acronym></em>

<legend id="3sh72"><pre id="3sh72"></pre></legend>

<dd id="3sh72"><track id="3sh72"></track></dd>

OPM-293平臺

化學成分確定的基礎培養基與高性能補料

OPM-293平臺包括化學成分確定的基礎培養基及補料，支持HEK293細胞株的高效率瞬時轉染和蛋白表達，亦可應用于腺相關病毒（AAV）、慢病毒（LV）和腺病毒（AdV）的高效率增殖，完美契合抗體藥、疫苗、細胞治療及基因治療相關需求。

產品特點：

提供DMF授權書
化學成分確定，提供TSE/BSE證明
符合GMP標準的生產
高密度懸浮培養及高效率瞬轉，支持蛋白高效表達，表達量高達g/L級別
經10＋基因治療藥物開發客戶驗證，成功完成IND申報。腺相關病毒（AAV）滴度高達2.29x10¹⁰ vg/mL，慢病毒（LV）滴度高達1x10⁷ TU/mL，腺病毒（AdV）滴度高達2x10⁹ IFU/mL
細胞性能測試中表現出優異的一致性（批次內&批次間RSD＜5%）
易于放大培養規模，在孔板、試管、搖瓶、Wave和大型生物反應器中具有一致的性能
提供液體（瓶裝或袋裝）和干粉形式包裝，規格可靈活定制
雙生產基地保障快速穩定供貨
靈活、專業、省心的售后服務

申請新品試用

產品信息表

產品名稱	貨號	劑型	規格	類型	SDS	描述
OPM-293 CD03 Medium	81070-001	液體	1000mL	化學成分確定培養基
OPM-293 CD03 DPM	91070-010	干粉	10L	化學成分確定培養基
OPM-293 CD03 DPM	91070-050	干粉	50L	化學成分確定培養基
OPM-293 CD05 Medium	81075-001	液體	1000mL	化學成分確定培養基
OPM-293 CD05 DPM	P688293	干粉	10L/50L/100L	化學成分確定培養基
OPM-CD Trans293	P82019	液體	1000mL	化學成分確定培養基
OPM-293 ProFeed	F081918	液體	100mL	無蛋白質補料
OPM-293 ProFeed DPM	C228293	干粉	10L	無蛋白質補料
OPM-293 ProFeed	F081918-001	液體	1000mL	無蛋白質補料
293F 表達系統試劑盒（Plus）	AC601500	液體	293F Hi-exp 培養基 1000ml 293F Hi-exp 補料 100ml CarpTrans 轉染試劑 5*1ml	化學成分確定培養基無蛋白質補料轉染試劑

使用奧浦邁產品發表的文獻

Close relatives of MERS-CoV in bats use ACE2 as their functional receptors
Nature. 2022 Dec;612(7941):748-757.
Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8
Nat Commun. 2022 Aug 25;13(1):4988.
Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay
Int J Biol Macromol. 2023 Jan 31;226:780-792.

查看更多

使用奧浦邁產品發表的文獻

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Nature. 2022 Dec;612(7941):748-757.
Specificity of TGF-β1 signal designated by LRRC33 and integrin αVβ8
Nat Commun. 2022 Aug 25;13(1):4988.
Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay
Int J Biol Macromol. 2023 Jan 31;226:780-792.
A novel and secure pseudovirus reporter system based assay for neutralizing and enhancing antibody assay against Marburg virus
Front Microbiol. 2022 Jun 9;13:927122.
Anti-Claudin18. 2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety
Int Immunopharmacol. 2022 Dec 28;115:109634.
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Sci Rep. 2022 Oct 26;12(1):18011.
Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
Adv Sci (Weinh). 2022 May;9(15):e2200063.
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
Front Immunol. 2022 May 27;13:920467.
Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo
Front Oncol. 2022 May 12;12:857927.
Screening and Identification of a Novel Anti–Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity
Mol Pharmacol. 2022 Sep;102(3):161-171.
Endodomain truncation of the HIV-1 envelope protein improves the packaging efficiency of pseudoviruses
Virology. 2022 Sep;574:1-8.
Preclinical characterization of a Fab-like CD3/CLDN18. 2 XFab? bispecific antibody against solid tumors
Immunobiology. 2022 Sep 30;227(6):152283.
Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain
FEBS Open Bio. 2022 Sep;12(9):1644-1656.
Novel application of anti‐human Fc nanobody for screening high‐producing CHO cells for monoclonal antibody
Eng Life Sci. 2022 Aug 23;22(10):608-618.
ORF8 protein of SARS‐CoV‐2 reduces male fertility in mice
J Med Virol. 2022 Sep;94(9):4193-4205.
S373P Mutation of Spike Protein in SARS-CoV-2 Stabilizes Omicron
Biorxiv.2022 July 19.
Augmenting Neutralization breadth against Diverse HIV-1 by increasing the Ab-Ag interface on V2
Adv Sci (Weinh). 2022 Mar 23;e2200063.
Structures of Omicron spike complexes and implications for neutralizing antibody development
Cell Rep. 2022 May 3;39(5):110770.
Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza
J Leukoc Biol. 2022 Jan 17.
Screening of Monoclonal Antibodies Targeting the Equine IgG1 Based on Single B Cell Antibodies Gene Amplification Technology
China Biotechnology. 2022, Vol. 42 Issue (4): 17-23.
Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine
Biorxiv.2022 May.
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
Nat Commun. 2021 Mar 1;12(1):1346.
An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Protein Cell. 2021 Sep 23;1-21.
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
Cell Rep. 2021 Feb 2;34(5):108699.
Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2. 2
Cell Rep. 2021 Nov 2;37(5):109931.
N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2
Elife. 2021 Aug 20;10:e69091.
Structure and Function of the Refined C-Terminal Loop in Imidazole Glycerol Phosphate Dehydratase from Different Homologs
J Agric Food Chem. 2021 Nov 24;69(46):13871-13880.
Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma
J Immunother. 2021 Apr 1;44(3):106-113.
Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys
Bioconjug Chem. 2021 May 19;32(5):1034-1046.
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
J Biol Eng. 2021 Jun 29;15(1):18.
Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy
Bioengineered. 2021 Dec;12(1):2095-2105.
Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2
Biorxiv. 2021 February 18.
Screening and Identification of a Novel Anti-siglec-15 Human Antibody 3F1 and the Research on Its Antitumor Activity
Papers.SSRN. 2021 Oct.
An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses
Immunol Lett. 2020 Jun;222:29-39.
Establishing 293T suspension cultrue for lentiviral vector production in a stirred bioreactor
Authorea. 2020 November 10.

案例展示

HEK293瞬時轉染培養基案例

支持高水平抗體瞬時表達
支持高水平病毒瞬時表達

OPM-CD Trans293 培養基支持重組蛋白或抗體的高水平瞬時表達，最高可達到1000mg/L以上

OPM-CD Trans293 培養基具有優異的批間穩定性

OPM-CD Trans293 培養基支持慢病毒（LV），腺病毒（AdV)以及腺相關病毒(AAV)的高水平瞬時表達。

OPM-CD Trans293+293 ProFeed 培養基與配套的293 ProFeed 補料可將病毒滴度提升50%以上，達到1x10⁷ TU/ml水平

使用 OPM-CD Trans293 培養基，得到的病毒滴度最高，工藝優化前即可達到2.29x10¹⁰ vg/ml水平。經過工藝優化，可以超過1x10¹¹ vg/ml

使用 OPM-CD Trans293 培養基，腺病毒滴度與某進口培養基一致（2x10⁹ IFU/mL）

常見問題

奧浦邁293瞬轉的產量一般在多少？
- 一般抗體可以達到(50-300)mg/L。
在使用293 CD05產蛋白后，下游經常出現鎳柱掉鎳，蛋白不純的情況，如何考慮改進？
- 可以建議客戶使用耐受EDTA的鎳柱，如GE 的Ni Excel。
OPM 293培養基可以用于細胞治療領域嗎？
- OPM 293-CD05搭配補料293-ProFeed，可以培養293FT細胞生產慢病毒（LV），慢病毒用于細胞治療的載體。
293瞬轉，客戶使用補料293-ProFeed后細胞活率下降快？
- 需要摸索293-ProFeed的濃度，可以嘗試分別補加5%，3%，7%。
奧浦邁培養基細菌內毒素控制在什么范圍？
- （1)基礎培養基控制在＜1.0 EU/ml，(2)補料控制在＜10 EU/ml，(3)超濃縮補料因為pH高，對內毒檢測有干擾，所以一般只是作為內控，客戶有要求的可以寫在COA上，如CDFS08
奧浦邁對CD培養基的定義是什么，包括Insulin和IgF-1嗎？
- 我們把胰島素和IgF-1也定義為CD，但培養基里若含有這些成分，我們會明確告知客戶。
補料中是否含有谷氨酰胺？
- 我們的補料中都不含谷氨酰胺；如含有谷氨酰胺，我們會標明。

快速導航

聯系我們

上海市浦東新區紫萍路908弄28號樓

4000-688-293（總機）

021-6818 2622（銷售）

021-6810 1106（CDMO BD）

客服郵箱：service@opmbiosciences.com

銷售郵箱：order@opmbiosciences.com

CDMO BD郵箱：cdmobd@opmbiosciences.com

請掃描二維碼關注奧浦邁官方公眾號

Copyright ? 2015-2022 上海奧浦邁生物科技股份有限公司 All Rights Reserved. 滬ICP備14035147號-3

訂
購
產
品

意
見
反
饋

申請新品試用

japanese精品少妇_18亚洲男同志 gay 网站_国产高清精品福利_亚洲另类欧美综合久久图片区